ClinicalTrials.gg
Not yet recruitingNCT07283198Updated Dec 15, 2025

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 interventional study of JSKN033 Injection in Non Small Cell Lung Cancer (NSCLC), sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, Phase II clinical study designed to evaluate the safety and efficacy of JSKN033 in the treatment of patients with advanced NSCLC. The study is divided into two phases: Part 1 (Dose Selection) and Part 2 (Cohort Expansion). Enrolled subjects are patients with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative treatment. Part 1 (Dose Selection): It consists of two dose groups, with a maximum of 20 subjects enrolled in each group. Part 2 (Cohort Expansion): It consists of two cohorts, with a maximum of 60 subjects enrolled in each cohort.

02

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)
03

In context

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 160 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects can understand the form,voluntarily participate in the study, and sign the informed consent form.
  2. Subjects are≥18 years old on the day of signing the informed consent form, regardless of gender.
  3. (ECOG) performance status score of 0 or 1.
  4. Expected survival time ≥3 months.
  5. or cytologically confirmed locally advanced or NSCLC (per AJCC 8th Edition Lung Cancer TNM Staging) that is not eligible for curative surgery and/or curative radiotherapy.
  6. NSCLC confirmed to be no other known driver gene alterations for which first- line targeted therapy has been approved.
  7. For Part 1(Dose Selection): Enrolled subjects are those with advanced unresectable or metastatic NSCLC who have failed or are intolerant to standard previous treatments, and have mutation or HER2 expression in tumor tissue.
  8. For Part 2 (Cohort Expansion): Enrolled subjects are those with locally advanced or metastatic NSCLC who have not received prior systemic anti-tumor treatment for their advanced disease.
  9. Per 1.1 criteria,subjects have at least one extracranial at baseline.
  10. Subjects must provide tumor tissue samples.
  11. Sufficient organ function.
  12. Female subjects of or male subjects whose partners are of childbearing potential agree to use highly effective measures from the time of signing the informed consent form until 24 weeks after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any small cell carcinoma component in the histological pathology.
  2. History of other malignant tumors within 5 years prior to the first dose administration.
  3. History of brainstem, meningeal, or spinal cord /compression, or carcinomatous meningitis; presence of active .
  4. Imaging during the screening phase shows tumor invasion, compression, or location in surrounding vital organs.
  5. Sufficient from previous treatments prior to the first dose.
  6. Presence of the following lung diseases or medical history leading to severe respiratory impairment.
  7. Presence of risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia.
  8. Presence of cardiovascular and cerebrovascular diseases or risk factors.
  9. Presence of uncontrolled infections.
  10. Toxicity from previous anti-tumor treatment has not recovered to grade≤1 (per v5.0).
  11. Previous history of allogeneic bone marrow or organ transplantation.
  12. Known allergy to any component of the study drug.
  13. Pregnant and/or lactating women, or women planning to become pregnant during the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part 1 (Dose Selection) and Part 2 (Cohort Expansion)

    JSKN033 is administered at the predefined dose, once per treatment cycle.

    Drug: JSKN033 Injection

Interventions

  • JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)

06

What researchers measure

Primary outcomes

  1. Number and Severity of Treatment-emergent Adverse Events (TEAEs)

    The incidence and severity of TEAEs and TRAEs (Treatment-related Adverse Events, graded according to NCI CTCAE 5.0), Serious AEs (SAEs), laboratory tests, etc.

    Time frame: Baseline up to 30 days after the last dose of study drug, up to 1 year

  2. Objective response rate (ORR)

    ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to 1 year after the last participant receives the last dose

Secondary outcomes

  1. Duration of response (DoR)

    Duration of response for responders (CR or PR) is defined as the time interval between the date of earliest qualifying response and the date of PD or death for any cause, whichever occurs earlier

    Time frame: Up to 1 year after the last participant receives the last dose

  2. Disease control rate (DCR)

    DCR was defined as the proportion of subjects whose best overall response is CR, PR, or Stable Disease (SD)

    Time frame: Up to 1 year after the last participant receives the last dose

  3. Clinical benefit rate (CBR)

    Clinical benefit rate (CR+PR+\[stable disease (SD) ≥ 6 months\]) is defined as those participants with best response as CR or PR or else SD with a duration of at least 6 months. SD for 6 months duration was defined as the time from the first dose to the first documentation of PD or to the last adequate response assessment prior to data cut-off date, whichever is earlier.

    Time frame: Up to 1 year after the last participant receives the last dose

  4. Progression-free Survival (PFS)

    PFS is defined as the time from the date of first study dose to disease progression or death whichever occurs first. Subjects without event (no disease progression or alive at last visit) will be censored at the date of "last tumor assessment".

    Time frame: Up to 1 year after the last participant receives the last dose

  5. Overall survival (OS)

    OS was defined as the time from the date of first dose until the date of death from any cause

    Time frame: Up to 1 year after the last participant receives the last dose

  6. PK parameter: Cmax

    Maximum (Peak) Observed blood Concentration (Cmax)

    Time frame: Post last dose up to Day 90

  7. PK parameter: Tmax

    Time of Maximum blood Concentration (Tmax)

    Time frame: Post last dose up to Day 90

  8. PK parameter: AUC

    The blood PK parameters of JSKN033 and its analytes for area under the concentration-versus-time curve from time 0 to the last quantifiable concentration as calculated by the linear-up log-down trapezoidal method (AUClast) and AUC from time 0 to infinity (AUCinf) elimination rate constant associated with the terminal phase were estimated using standard non-compartmental methods.

    Time frame: Post last dose up to Day 90

  9. PK parameter: Terminal Elimination Half-life (t1/2)

    Time frame: Post last dose up to Day 90

  10. PK parameter: Volume of distribution (V)

    Time frame: Post last dose up to Day 90

  11. PK parameter: trough concentration (Ctrough)

    Time frame: Post last dose up to Day 90

  12. PK parameter: Clearance (CL)

    Time frame: Post last dose up to Day 90

  13. PK parameter: Accumulation index (Rac)

    Time frame: Post last dose up to Day 90

  14. PK parameter: Mean residence time (MRT)

    Time frame: Post last dose up to Day 90

  15. Incidence of anti-drug antibodies (ADAs), antibody titers, and incidence of neutralizing antibodies

    Time frame: Post last dose up to Day 90

Other outcomes

  1. Correlation between biomarkers (HER2 mutation status, HER2/PD-L1 expression levels) in tumor tissue samples and efficacy.

    Time frame: Up to 1 year after the last participant receives the last dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Aug 2027, 20 months later.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 20 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 15, 2025
StartEst.
Dec 10, 2025
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07283198
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Dec 15, 2025

Study contacts

Lin Wu, Doctor
Contact
wulin-calf@vip.163.com
+86 731 8976 2300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JSKN033

Start the discussion